Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study
| Autor: | Christian Ukena, Gunnar H. Heine, Sarah Seiler-Mussler, Dominic Kaddu-Mulindwa, Insa E. Emrich, R. D’Amelio, Stefan Wagenpfeil, Vincent Brandenburg, Danilo Fliser, Fabio Lizzi, Michael Böhm, J. D. Siegel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Hypophosphatemia Urinary system Iron lcsh:Medicine 030226 pharmacology & pharmacy Gastroenterology Ferric Compounds 03 medical and health sciences 0302 clinical medicine Double-Blind Method FGF23 Internal medicine medicine Clinical endpoint Humans Ferric derisomaltose Prospective Studies Maltose biology Anemia Iron-Deficiency business.industry Transferrin saturation lcsh:R General Medicine medicine.disease Ferric carboxymaltose Ferritin Fibroblast Growth Factor-23 Iron-deficiency anemia Iron deficiency anemia biology.protein Ferric Female Hemoglobin business 030217 neurology & neurosurgery medicine.drug Research Article |
| Zdroj: | BMC Medicine BMC Medicine, Vol 18, Iss 1, Pp 1-10 (2020) |
| ISSN: | 1741-7015 |
| Popis: | Background In patients with iron deficiency anemia, ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) allow high-dose iron repletion. While FCM is reported to induce hypophosphatemia, the frequency of hypophosphatemia after an equivalent dosage of FDI had not been assessed prospectively. Methods In the prospective, single-center, double-blind HOMe aFers study, 26 women with iron deficiency anemia (hemoglobin Results Hypophosphatemia occurred more frequently in women treated with FCM (9 out of 12 [75%]) than in those treated with FDI (1 out of 13 [8%]; p = 0.001). Within 24 h after iron supplementation, women in the FCM group had significant higher plasma intact FGF23 (p p p = 0.021 at day 7 ± 2 after iron supplementation). We did not observe differences in skeletal and cardiovascular markers, potentially because of the limited number of participants. Conclusions While both FCM and FDI provide efficient iron repletion in participants with iron deficiency anemia, FCM induced hypophosphatemia more often than FDI. Trial registration Clinical Trials.gov NCT02905539. Registered on 8 September 2016. 2015-004808-36 (EudraCT Number) U1111-1176-4563 (WHO Universal Trial Number) DRKS00010766 (Deutsches Register Klinischer Studien) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink